AgingResearch.NewsJoin free

Epirium Bio

CompanyUnited States

Epirium Bio develops 2 assets, the furthest in phase 2 (MF-300 in sarcopenia). Mostly small molecule acting on HPGD; based in the United States.

2
Assets
Furthest stage
Phase 2
0
Trials
0
Signals

Pipeline

2

  • MF-300

    Inhibits 15-PGDH.

    Phase 2, Small molecule, HPGD, sarcopenia

  • EPM-01

    Phase 1, Becker muscular dystrophy

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • People23
  • Similar companies6

Papers

Intelligence